RT 100

Drug Profile

RT 100

Alternative Names: Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 04 Aug 2017 RT 100 is still in phase II development for Heart failure in USA (Renova Therapeutics, August 2017)
  • 02 Aug 2017 Pharmacodynamics data from a preclinical study in Heart failure released by Renova Therapeutics
  • 01 Nov 2016 Renova Therapeutics plans the phase III FLOURISH trial for Heart failure in USA in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top